Metsera (NASDAQ:MTSR - Get Free Report) announced its earnings results on Monday. The company reported ($1.03) EPS for the quarter, Zacks reports.
Metsera Trading Down 3.6%
NASDAQ MTSR opened at $23.88 on Monday. Metsera has a 12 month low of $12.30 and a 12 month high of $32.81. The business has a 50-day moving average of $22.80.
Analyst Ratings Changes
A number of brokerages have commented on MTSR. Bank of America assumed coverage on Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 price target for the company. Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an "overweight" rating for the company. Guggenheim assumed coverage on Metsera in a report on Tuesday, February 25th. They issued a "buy" rating and a $56.00 target price for the company. Finally, Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an "outperform" rating on the stock.
Read Our Latest Analysis on MTSR
About Metsera
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
